Loading clinical trials...
Loading clinical trials...
Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial."
Conditions
Interventions
Ponatinib 30 MG
Locations
14
France
CHU Angers
Angers, France
CHu Brest
Brest, France
CHU Caen
Caen, France
CHU Clermont Ferrand
Clermont-Ferrand, France
CHU Grenoble
Grenoble, France
CHU Lille
Lille, France
Start Date
December 2, 2019
Primary Completion Date
December 5, 2023
Completion Date
December 31, 2024
Last Updated
March 25, 2025
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06326268
Lead Sponsor
Versailles Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions